Evogene (NASDAQ:EVGN – Get Free Report) is scheduled to issue its 09/30/2023 quarterly earnings data before the market opens on Wednesday, November 15th. Analysts expect the company to announce earnings of ($0.17) per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.
Evogene (NASDAQ:EVGN – Get Free Report) last posted its quarterly earnings results on Thursday, August 17th. The biotechnology company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.02. The business had revenue of $0.65 million for the quarter, compared to analysts’ expectations of $0.77 million. Evogene had a negative return on equity of 68.84% and a negative net margin of 943.25%. During the same period last year, the firm earned ($0.21) earnings per share. On average, analysts expect Evogene to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Evogene Stock Up 2.3 %
NASDAQ EVGN opened at $0.57 on Monday. Evogene has a twelve month low of $0.45 and a twelve month high of $1.44. The business has a 50-day moving average price of $0.59 and a 200-day moving average price of $0.75. The firm has a market cap of $23.30 million, a price-to-earnings ratio of -1.03 and a beta of 1.38.
Institutional Inflows and Outflows
Analyst Ratings Changes
EVGN has been the subject of several recent analyst reports. Lake Street Capital upped their price target on Evogene from $2.00 to $3.00 and gave the stock a “buy” rating in a research note on Friday, August 18th. StockNews.com raised shares of Evogene to a “sell” rating in a research note on Thursday, October 26th. Roth Mkm lifted their price target on shares of Evogene from $1.00 to $6.00 and gave the company a “buy” rating in a report on Friday, July 21st. Finally, Alliance Global Partners assumed coverage on shares of Evogene in a report on Monday, October 2nd. They set a “buy” rating and a $1.85 price objective for the company.
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.
- Five stocks we like better than Evogene
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- MarketBeat Week in Review – 11/6 – 11/10
- Trading Halts Explained
- Data giants MongoDB and Snowflake just got upgraded
- Best Stocks Under $5.00
- Plug Power at tipping point; it’s make or break time for hydrogen
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.